Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
296.8 DKK | +2.34% | +3.56% | -23.51% |
04-12 | Chemometec A/S Reports Revenue for the Third Quarter and First Nine Months of 2023 -2024 | CI |
04-12 | ChemoMetec A/S Provides Earnings Guidance for the Year 2023/24 | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analyst opinion has improved significantly over the past four months.
Weaknesses
- The company's earnings growth outlook lacks momentum and is a weakness.
- With an expected P/E ratio at 38.57 and 32.92 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is highly valued given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last few months, analysts have been revising downwards their earnings forecast.
- Over the past twelve months, analysts' opinions have been revised negatively.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-23.51% | 746M | D | ||
+73.37% | 12.39B | B- | ||
-17.09% | 8.08B | C+ | ||
+16.88% | 7.25B | C- | ||
+3.57% | 5.86B | B | ||
+11.77% | 5.35B | D+ | ||
+29.65% | 4.63B | - | ||
-17.74% | 4.19B | B- | ||
-35.26% | 2.44B | C | ||
+3.09% | 2.07B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- CHEMM Stock
- Ratings ChemoMetec A/S